NASDAQ:NBRVNabriva Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Nabriva Therapeutics PLC - Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.70 -0.02 (-3.31 %) (As of 08/12/2020 01:10 PM ET) Add Compare Share Today's Range$0.69Now: $0.70▼$0.7150-Day Range$0.64MA: $0.75▼$0.9152-Week Range$0.49Now: $0.70▼$2.77Volume14,793 shsAverage Volume5.10 million shsMarket Capitalization$995.27 millionP/E RatioN/ADividend YieldN/ABeta2.41 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Nabriva Therapeutics plc, a biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. Its lead product candidate is lefamulin, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia; and has completed Phase II clinical trials for the treatment of acute bacterial skin and skin structure infection. The company is also developing CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections. In addition, it is developing lefamulin for use in the treatment of ventilator-associated bacterial pneumonia or hospital-acquired bacterial pneumonia and sexually transmitted infections, as well as Pediatric oral formulation. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.Read More Beat the Market (BTM) Rank™ 3.2 Analyst's Opinion Consensus RatingNabriva Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $3.75, Nabriva Therapeutics has a potential upside of 420.8% from its current price of $0.72.Amount of Analyst CoverageNabriva Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 2.7 Community Rank Outperform VotesNabriva Therapeutics has received 374 “outperform” votes. (Add your “outperform” vote.)Underperform VotesNabriva Therapeutics has received 309 “underperform” votes. (Add your “underperform” vote.)Community SentimentNabriva Therapeutics has received 54.76% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Nabriva Therapeutics and other stocks. Vote “Outperform” if you believe NBRV will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NBRV will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldNabriva Therapeutics does not currently pay a dividend.Dividend GrowthNabriva Therapeutics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Nabriva Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.76% of the stock of Nabriva Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 1.60% of the stock of Nabriva Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Nabriva Therapeutics are expected to grow in the coming year, from ($0.59) to ($0.37) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nabriva Therapeutics is -0.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nabriva Therapeutics is -0.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNabriva Therapeutics has a P/B Ratio of 18.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.2Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.30 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NBRV Previous Symbol CUSIPN/A CIK1641640 Webwww.nabriva.com Phone353-1649-2000Debt Debt-to-Equity Ratio0.17 Current Ratio5.68 Quick Ratio5.20Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$9.48 million Price / Sales104.99 Cash FlowN/A Price / Cash FlowN/A Book Value$0.04 per share Price / Book17.41Profitability EPS (Most Recent Fiscal Year)($1.12) Net Income$-82,760,000.00 Net Margins-932.58% Return on Equity-212.02% Return on Assets-105.80%Miscellaneous Employees162 Outstanding Shares1,429,580,000Market Cap$995.27 million Next Earnings Date11/10/2020 (Estimated) OptionableOptionable $0.70 -0.02 (-3.31 %) (As of 08/12/2020 01:10 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive NBRV News and Ratings via Email Sign-up to receive the latest news and ratings for NBRV and its competitors with MarketBeat's FREE daily newsletter. Nabriva Therapeutics (NASDAQ:NBRV) Frequently Asked Questions How has Nabriva Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Nabriva Therapeutics' stock was trading at $1.21 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, NBRV stock has decreased by 42.5% and is now trading at $0.6962. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Nabriva Therapeutics? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nabriva Therapeutics in the last year. There are currently 4 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Nabriva Therapeutics. When is Nabriva Therapeutics' next earnings date? Nabriva Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020. View our earnings forecast for Nabriva Therapeutics. How were Nabriva Therapeutics' earnings last quarter? Nabriva Therapeutics PLC - (NASDAQ:NBRV) announced its quarterly earnings results on Thursday, August, 6th. The biotechnology company reported ($0.14) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.16) by $0.02. Nabriva Therapeutics had a negative net margin of 932.58% and a negative return on equity of 212.02%. View Nabriva Therapeutics' earnings history. What price target have analysts set for NBRV? 6 brokerages have issued 1-year target prices for Nabriva Therapeutics' shares. Their forecasts range from $1.00 to $7.00. On average, they expect Nabriva Therapeutics' share price to reach $3.75 in the next year. This suggests a possible upside of 438.6% from the stock's current price. View analysts' price targets for Nabriva Therapeutics. Has Nabriva Therapeutics been receiving favorable news coverage? News coverage about NBRV stock has been trending negative on Wednesday, InfoTrie Sentiment reports. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Nabriva Therapeutics earned a coverage optimism score of -2.2 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the near future. View the latest news about Nabriva Therapeutics. Are investors shorting Nabriva Therapeutics? Nabriva Therapeutics saw a decline in short interest in March. As of March 13th, there was short interest totaling 3,619,900 shares, a decline of 33.9% from the February 27th total of 5,480,000 shares. Based on an average daily volume of 1,102,100 shares, the days-to-cover ratio is currently 3.3 days. View Nabriva Therapeutics' Short Interest. Who are some of Nabriva Therapeutics' key competitors? Some companies that are related to Nabriva Therapeutics include Legend Biotech (LEGN), HYPERA S A/S (HYPMY), Amicus Therapeutics (FOLD), Nektar Therapeutics (NKTR), Arena Pharmaceuticals (ARNA), Global Blood Therapeutics (GBT), Biohaven Pharmaceutical (BHVN), Reata Pharmaceuticals (RETA), BridgeBio Pharma (BBIO), GW Pharmaceuticals PLC- (GWPH), ChemoCentryx (CCXI), Opko Health (OPK), PTC Therapeutics (PTCT), Insmed (INSM) and Axsome Therapeutics (AXSM). View all competitors. What other stocks do shareholders of Nabriva Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Nabriva Therapeutics investors own include SCYNEXIS (SCYX), Agile Therapeutics (AGRX), VBI Vaccines (VBIV), Dynavax Technologies (DVAX), AcelRx Pharmaceuticals (ACRX), Amarin (AMRN), Sorrento Therapeutics (SRNE), Vaxart (VXRT), Zynerba Pharmaceuticals (ZYNE) and Acasti Pharma (ACST). Who are Nabriva Therapeutics' key executives? Nabriva Therapeutics' management team includes the following people: Mr. Theodore R. Schroeder, CEO & Director (Age 65, Pay $707.62k)Mr. Steven P. Gelone, Pres & COO (Age 52, Pay $667.5k)Dr. Colin Broom, Director (Age 64, Pay $39.13k)Dr. Jennifer Schranz M.D., Chief Medical Officer (Age 55, Pay $620.85k)Mr. Gary L. Sender, Chief Financial Officer (Age 58) What is Nabriva Therapeutics' stock symbol? Nabriva Therapeutics trades on the NASDAQ under the ticker symbol "NBRV." Who are Nabriva Therapeutics' major shareholders? Nabriva Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include WINTON GROUP Ltd (0.03%), Clear Creek Financial Management LLC (0.02%), Integrated Wealth Concepts LLC (0.01%), Exane Derivatives (0.01%) and Virtu Financial LLC (0.00%). Company insiders that own Nabriva Therapeutics stock include Charles A Rowland Jr, Colin Md Broom, Francesco Maria Lavino, Gary Sender, Steven P Gelone and Theodore R Schroeder. View institutional ownership trends for Nabriva Therapeutics. Which major investors are buying Nabriva Therapeutics stock? NBRV stock was acquired by a variety of institutional investors in the last quarter, including WINTON GROUP Ltd, Integrated Wealth Concepts LLC, Clear Creek Financial Management LLC, Virtu Financial LLC, and Exane Derivatives. Company insiders that have bought Nabriva Therapeutics stock in the last two years include Charles A Rowland Jr, Colin Md Broom, Francesco Maria Lavino, and Theodore R Schroeder. View insider buying and selling activity for Nabriva Therapeutics. How do I buy shares of Nabriva Therapeutics? Shares of NBRV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Nabriva Therapeutics' stock price today? One share of NBRV stock can currently be purchased for approximately $0.70. How big of a company is Nabriva Therapeutics? Nabriva Therapeutics has a market capitalization of $995.27 million and generates $9.48 million in revenue each year. The biotechnology company earns $-82,760,000.00 in net income (profit) each year or ($1.12) on an earnings per share basis. Nabriva Therapeutics employs 162 workers across the globe. What is Nabriva Therapeutics' official website? The official website for Nabriva Therapeutics is www.nabriva.com. How can I contact Nabriva Therapeutics? Nabriva Therapeutics' mailing address is 25-28 NORTH WALL QUAY IFSC, DUBLIN 1 L2, 19406. The biotechnology company can be reached via phone at 353-1649-2000 or via email at [email protected] This page was last updated on 8/12/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
